86 related articles for article (PubMed ID: 38557494)
1. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
Li C; Wang T; Song J
Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
Ni K; Meng L
Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102381. PubMed ID: 38821484
[TBL] [Abstract][Full Text] [Related]
3. RASSF4 Attenuates Metabolic Dysfunction-Associated Steatotic Liver Disease Progression via Hippo Signaling and Suppresses Hepatocarcinogenesis.
Xu C; Fang T; Qu J; Miao Y; Tian L; Zhang M; Zhuang H; Sun B; Chen L
Cell Mol Gastroenterol Hepatol; 2024 Apr; 18(2):101348. PubMed ID: 38697356
[TBL] [Abstract][Full Text] [Related]
4. Myocardial infarction accelerates the progression of MASH by triggering immunoinflammatory response and induction of periosti.
Xie W; Gan J; Zhou X; Tian H; Pan X; Liu W; Li X; Du J; Xu A; Zheng M; Wu F; Li Y; Lin Z
Cell Metab; 2024 Jun; 36(6):1269-1286.e9. PubMed ID: 38838640
[TBL] [Abstract][Full Text] [Related]
5. Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
Sokal-Dembowska A; Jarmakiewicz-Czaja S; Ferenc K; Filip R
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791276
[TBL] [Abstract][Full Text] [Related]
6. Suppression of hepatic ChREBP⍺-CYP2C50 axis-driven fatty acid oxidation sensitizes mice to diet-induced MASLD/MASH.
Zhang D; Zhao Y; Zhang G; Lank D; Cooke S; Wang S; Nuotio-Antar A; Tong X; Yin L
Mol Metab; 2024 May; 85():101957. PubMed ID: 38740087
[TBL] [Abstract][Full Text] [Related]
7. Hepatic glucose metabolism in the steatotic liver.
Scoditti E; Sabatini S; Carli F; Gastaldelli A
Nat Rev Gastroenterol Hepatol; 2024 May; 21(5):319-334. PubMed ID: 38308003
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular RECK as a Critical Regulator of Metabolic Dysfunction-Associated Steatohepatitis Development.
Dashek RJ; Cunningham RP; Taylor CL; Alessi I; Diaz C; Meers GM; Wheeler AA; Ibdah JA; Parks EJ; Yoshida T; Chandrasekar B; Rector RS
Cell Mol Gastroenterol Hepatol; 2024 May; ():101365. PubMed ID: 38797477
[TBL] [Abstract][Full Text] [Related]
9. Role and therapeutic perspectives of extracellular vesicles derived from liver and adipose tissue in metabolic dysfunction-associated steatotic liver disease.
Li W; Yu L
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):355-369. PubMed ID: 38833340
[TBL] [Abstract][Full Text] [Related]
10. Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
Moore MP; Wang X; Kennelly JP; Shi H; Ishino Y; Kano K; Aoki J; Cherubini A; Ronzoni L; Guo X; Chalasani NP; Khalid S; Saleheen D; Mitsche MA; Rotter JI; Yates KP; Valenti L; Kono N; Tontonoz P; Tabas I
Hepatology; 2024 May; ():. PubMed ID: 38776184
[TBL] [Abstract][Full Text] [Related]
11. Metabolic reprogramming in liver fibrosis.
Horn P; Tacke F
Cell Metab; 2024 May; ():. PubMed ID: 38823393
[TBL] [Abstract][Full Text] [Related]
12. Τ cell-mediated adaptive immunity in the transition from metabolic dysfunction-associated steatohepatitis to hepatocellular carcinoma.
Papadopoulos G; Giannousi E; Avdi AP; Velliou RI; Nikolakopoulou P; Chatzigeorgiou A
Front Cell Dev Biol; 2024; 12():1343806. PubMed ID: 38774646
[TBL] [Abstract][Full Text] [Related]
13. Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression.
Maretti-Mira AC; Salomon MP; Chopra S; Yuan L; Golden-Mason L
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791066
[TBL] [Abstract][Full Text] [Related]
14. New and emerging treatments for metabolic dysfunction-associated steatohepatitis.
Tincopa MA; Anstee QM; Loomba R
Cell Metab; 2024 May; 36(5):912-926. PubMed ID: 38608696
[TBL] [Abstract][Full Text] [Related]
15. New and emerging treatments for metabolic dysfunction-associated steatohepatitis.
Tincopa MA; Anstee QM; Loomba R
Cell Metab; 2024 Jun; 36(6):1430. PubMed ID: 38670106
[No Abstract] [Full Text] [Related]
16. Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis.
Steffani M; Geng Y; Pajvani UB; Schwabe RF
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557494
[TBL] [Abstract][Full Text] [Related]
17. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
[TBL] [Abstract][Full Text] [Related]
18. Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
Bendixen SM; Jakobsgaard PR; Hansen D; Hejn KH; Terkelsen MK; Bjerre FA; Thulesen AP; Eriksen NG; Hallenborg P; Geng Y; Dam TV; Larsen FT; Wernberg CW; Vijayathurai J; Scott EAH; Marcher AB; Detlefsen S; Grøntved L; Dimke H; Berdeaux R; de Aguiar Vallim TQ; Olinga P; Lauridsen MM; Krag A; Blagoev B; Ravnskjaer K
J Hepatol; 2024 Mar; 80(3):467-481. PubMed ID: 37972658
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression.
Yan T; Yan N; Xia Y; Sawaswong V; Zhu X; Dias HB; Aibara D; Takahashi S; Hamada K; Saito Y; Li G; Liu H; Yan H; Velenosi TJ; Krausz KW; Huang J; Kimura S; Rotman Y; Qu A; Hao H; Gonzalez FJ
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557493
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
